Abstract
We report the case of a 43-year-old male patient with persistent multifocal, skin-restricted, CD30-positive, large T-cell lymphoma. Combination therapy of systemic interferon alfa and oral bexarotene was initiated on an experimental basis in the hope of circumventing therapies such as methotrexate, radiotherapy, or multiple-agent chemotherapy that may be required in such cases. This treatment was associated with rapid and marked regression of the patient's cutaneous lesions.
Publication types
-
Case Reports
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Administration, Oral
-
Adult
-
Anticarcinogenic Agents / administration & dosage*
-
Antineoplastic Agents / administration & dosage*
-
Bexarotene
-
Drug Therapy, Combination
-
Humans
-
Interferon-alpha / administration & dosage*
-
Ki-1 Antigen / analysis*
-
Lymphoma, T-Cell, Cutaneous / drug therapy*
-
Lymphoma, T-Cell, Cutaneous / pathology
-
Male
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / pathology
-
Tetrahydronaphthalenes / administration & dosage*
Substances
-
Anticarcinogenic Agents
-
Antineoplastic Agents
-
Interferon-alpha
-
Ki-1 Antigen
-
Tetrahydronaphthalenes
-
Bexarotene